GlaxoSmithKline (GSK.US) has launched a 2nd phase single-arm clinical trial of Mottalib monoclonal antibody in China.
China's Clinical Trial Register and Information Public Platform's website recently updated the latest information that GlaxoSmithKline (GSK.US) has launched a Phase II single-arm clinical study of dostarlimab in China for patients with locally advanced dMMR/MSI-H rectal cancer who have not received prior treatment.
According to the public information, dostarlimab is an anti-PD-1 antibody, which was first approved for clinical use in China in July this year. GSK recently published the latest long-term data from the first-line treatment of dMMR/MSI-H locally advanced rectal cancer in a Phase II clinical trial. In the study, 100% of patients treated with the trial drug achieved complete clinical response (cCR). The Phase II clinical study launched in China is targeting the same indication.
Image source: China's Clinical Trial Register and Information Public Platform's website
Dostarlimab is a PD-1-blocking antibody that binds to the PD-1 receptor and blocks its interaction with its ligands, PD-L1 and PD-L2. The product has been approved by the FDA for multiple indications, including dMMR advanced or recurrent endometrial cancer, dMMR or MSI-H primary advanced or recurrent endometrial cancer, dMMR recurrent or advanced solid tumors. In addition, GSK is continuing to explore the therapeutic potential of the drug in multiple ongoing Phase III clinical trials.